Phase 3 Clinical Trials With Primary Completion Dates in May 2018

This is a list of Phase 3 trials with primary completion dates in May 2018 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ALKS Alkermes plc 2018-05-01 Phase 3 NCT02110264 Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)
FGEN FibroGen, Inc 2018-05-01 Phase 3 NCT02988973 A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
ICLR ICON plc 2018-05-01 Phase 3 NCT02065882 Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency
KMPH KemPharm, Inc. 2018-05-01 Phase 3 NCT03292952 KP415 Classroom Study in Children (6-12 Years of Age) With ADHD
PRAH PRA Health Sciences, Inc. 2018-05-01 Phase 3 NCT02552212 Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
SHPG Shire plc 2018-05-01 Phase 3 NCT02998554 Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo
SHPG Shire plc 2018-05-01 Phase 3 NCT02998541 Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo
SHPG Shire plc 2018-05-01 Phase 3 NCT02093663 Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis
SHPG Shire plc 2018-05-01 Phase 3 NCT02895945 BAX 802 in CHA With Inhibitors
SUPN Supernus Pharmaceuticals, Inc. 2018-05-01 Phase 3 NCT02618434 Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
TSRO TESARO, Inc. 2018-05-01 Phase 3 NCT01905592 A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients